Pozen (Nasdaq: POZN) is seeking a preliminary injunction to block the sale of a generic version of its pain reliever Treximet.

Pozen is partnered with GlaxoSmithKline (NYSE: GSK) to sell Treximet.

The Chapel Hill-based firm is seeking the restraining order in federal court in Texas against Par Pharmaceuticals. It is fighting Par, Alphapharm and Dr. Reddy’s in one consolidated suit about Treximet generics. The case was tried last October, but a decision is still pending.

For details, read here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter